In the past week, TRVI stock has gone up by 2.71%, with a monthly decline of -20.90% and a quarterly surge of 98.50%. The volatility ratio for the week is 13.31%, and the volatility levels for the last 30 days are 8.80% for Trevi Therapeutics Inc The simple moving average for the last 20 days is -12.03% for TRVI stock, with a simple moving average of 27.87% for the last 200 days.
Is It Worth Investing in Trevi Therapeutics Inc (NASDAQ: TRVI) Right Now?
The 36-month beta value for TRVI is at 0.92. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TRVI is 45.90M, and currently, shorts hold a 2.28% of that float. The average trading volume for TRVI on April 25, 2024 was 302.81K shares.
TRVI) stock’s latest price update
Trevi Therapeutics Inc (NASDAQ: TRVI)’s stock price has decreased by -7.02 compared to its previous closing price of 2.85. However, the company has seen a 2.71% increase in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-18 that Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock’s potential for a turnaround in the near term.
Analysts’ Opinion of TRVI
Many brokerage firms have already submitted their reports for TRVI stocks, with B. Riley Securities repeating the rating for TRVI by listing it as a “Buy.” The predicted price for TRVI in the upcoming period, according to B. Riley Securities is $6 based on the research report published on April 12, 2023 of the previous year 2023.
SVB Leerink, on the other hand, stated in their research note that they expect to see TRVI reach a price target of $6. The rating they have provided for TRVI stocks is “Outperform” according to the report published on November 22nd, 2022.
SVB Leerink gave a rating of “Outperform” to TRVI, setting the target price at $14 in the report published on June 03rd of the previous year.
TRVI Trading at -9.69% from the 50-Day Moving Average
After a stumble in the market that brought TRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.75% of loss for the given period.
Volatility was left at 8.80%, however, over the last 30 days, the volatility rate increased by 13.31%, as shares sank -21.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +49.72% upper at present.
During the last 5 trading sessions, TRVI rose by +2.71%, which changed the moving average for the period of 200-days by +12.29% in comparison to the 20-day moving average, which settled at $2.98. In addition, Trevi Therapeutics Inc saw 97.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TRVI starting from Delfini Lisa, who sale 785 shares at the price of $2.02 back on Oct 11 ’23. After this action, Delfini Lisa now owns 35,901 shares of Trevi Therapeutics Inc, valued at $1,586 using the latest closing price.
Delfini Lisa, the Chief Financial Officer of Trevi Therapeutics Inc, sale 711 shares at $2.20 during a trade that took place back on Sep 11 ’23, which means that Delfini Lisa is holding 34,394 shares at $1,564 based on the most recent closing price.
Stock Fundamentals for TRVI
The total capital return value is set at -0.41. Equity return is now at value -30.59, with -27.37 for asset returns.
Based on Trevi Therapeutics Inc (TRVI), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -23.7. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -104.7.
Currently, EBITDA for the company is -33.8 million with net debt to EBITDA at 0.96. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.03.
Conclusion
In conclusion, Trevi Therapeutics Inc (TRVI) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
